Search
for
Sort by
Research
30-60 / 1000+ results
research Retrospective Pharmacotherapeutic Evaluation of Dutasteride not Approved by US FDA for Androgenetic Alopecia in Korea
Dutasteride is highly effective for hair loss treatment in Korea, with more side effects than finasteride.
research Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
Five FDA-approved drugs may help block COVID-19 virus entry.
research Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
Apremilast shows promise for several skin conditions but needs more research.
research Unequal Protection Under the Law: Why FDA Should Use Negotiated Rulemaking to Reform the Regulation of Generic Drugs
The FDA should use negotiated rulemaking to improve generic drug safety regulations.
research Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches
Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.
research Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods
Five FDA-approved drugs may help block COVID-19 virus entry.
research Not Its Crowning Glory: Obstacles for FDA in Regulating Ingested Dietary Supplements Purporting to Prevent Hair Loss
The FDA struggles to regulate hair loss supplements due to a law allowing unproven claims.
research The Possible Role of Prescribing Medications, Including Central Nervous System Drugs, in Contributing to Male-Factor Infertility (MFI): Assessment of the Food and Drug Administration (FDA) Pharmacovigilance Database
Some medications might contribute to male infertility, with finasteride showing a high number of reports.
research Repurposing of Linagliptin Similar FDA Approved Drugs as Antidiabetic Agents
Pranlukast and mirabegron may work as new diabetes drugs.
research The US FDA has approved the marketing of generic finasteride 5mg tablets by Actavis.
research Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
Statins may be linked to reproductive organ conditions, and their risks should be monitored.
research Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system
A pharmacovigilance study using the FDA Adverse Event Reporting System identified 1,389 cases of cutaneous adverse events (AEs) associated with enfortumab vedotin (EV), a treatment for urothelial carcinoma. Common AEs included rash, pruritus, and alopecia, with severe reactions like Stevens–Johnson syndrome. The study found 44 positive safety signals, 10 of which were previously unlabeled. Most AEs occurred within the first 2 weeks of treatment, primarily in elderly males. Concomitant prednisolone use increased AE reporting and mortality, while amlodipine use decreased AE reporting. These findings underscore the need for early dermatologic surveillance and personalized safety management during EV therapy.
research Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system
Paternal drug exposure can harm fertility, pregnancy outcomes, and offspring health, with specific drugs linked to various reproductive issues.
research 112 Post-Finasteride Syndrome – Outcomes of FDA Database
research Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
EGFR-TKIs can cause significant skin, nail, and organ side effects.
research Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
research Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.
research Inconsistent platelet-rich plasma product from devices cleared by the US FDA: A retrospective review of clinic data
PRP treatments for hair loss need standard protocols to be reliable.
research Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules
The methods accurately measure finasteride and tadalafil in Entadfi™ capsules for quality control.
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research Innovations in skin microphysiological systems for nonclinical testing and FDA modernization
New technologies replicate human skin for testing without animals.
research PD29-07 DRUGS ASSOCIATED THE MOST WITH MALE-FACTOR INFERTILITY: ASSESSMENT OF THE 2010-2020 FOOD AND DRUG ADMINISTRATION (FDA) PHARMACOVIGILANCE DATABASE
Finasteride and testosterone are the drugs most linked to male infertility, but many other potential drugs may be under-reported.
research 0557 Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea (OSA): Results from the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS)
Some drugs may increase the risk of obstructive sleep apnea, while others like certain biologics might decrease it.
research 054 Post Finasteride Syndrome: Guess Who-Demographics from FDA Database
Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.
research A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir
The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research Sustainable UV approaches supported by greenness and whiteness assessments for estimating a recently FDA-approved combination for managing urologic disorders: Tukey's test
New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
research 0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS)
Finasteride increases risk of sleep apnea and insomnia.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.